|
Active substance |
obeticholic acid |
|
Holder |
Intercept Pharma Nederland BV |
|
Status |
Running |
|
Indication |
Treatment of patients with Primary Biliary cholangitis who completed the Long-Term Safety Extension of the POISE phase 3 trial (747-301 / EudraCT 2011-004728-36) |
|
Public documents |
|
|
Last update |
23/03/2023 |
Ocaliva®
Last updated on 23/03/2023